US Ophthalmic Drugs Market Size study, by Drug Class (Anti-glaucoma Drugs, Dry Eye Drugs, Ophthalmic Anti-allergy/Inflammatory, Retinal Drugs, Anti-infective Drugs, Other Drugs), by Product Type (OTC Drugs, Prescription Drugs) Forecasts 2022-2032
US Ophthalmic Drugs Market is valued at approximately USD 11.93 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.69% over the forecast period 2024-2032. Ophthalmic drugs represent a specialized class of medications crafted to address a myriad of eye ailments and conditions. These therapeutic agents offer versatile delivery methods, including eye drops, ointments, gels, and injections, tailored to suit individual needs. They serve as invaluable tools in the management of diverse ocular concerns spanning from infections and inflammation to glaucoma, allergies, dry eye syndrome, and beyond, ensuring comprehensive care for eye health. Also, technological advancements in drug delivery systems, such as sustained-release implants, punctal plugs, and nanotechnology-based formulations, are enhancing the effectiveness and convenience of ophthalmic drug therapies. These innovations are attracting both patients and healthcare providers, thereby support the growth of Ophthalmic Drugs Market.
Moreover, the rising prevalence of eye disorders such as glaucoma, macular degeneration, diabetic retinopathy, and cataracts is driving the demand for ophthalmic drugs. As the population ages and chronic conditions become more prevalent, the need for treatments for these diseases grows. Also, the increasing healthcare expenditure in the US, coupled with better access to healthcare services, allows more patients to seek treatment for eye disorders, thereby driving the demand for ophthalmic drugs. However, the risks associated with ophthalmic pharmaceuticals, as well as the longer timeline required for ophthalmic drug development, are projected to impede market expansion in the Ophthalmic drugs Market during 2024 to 2032.
Major market player included in this report are:Bausch Health Companies Inc.
Merck & Co., Inc
Genentech, Inc.
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10
The detailed segments and sub-segment of the market are explained below: By Drug Class
Anti-glaucoma Drugs
Dry Eye Drugs
Ophthalmic Anti-allergy/Inflammatory
Retinal Drugs
Anti-infective Drugs
Other Drugs
By Product Type
OTC Drugs
Prescription Drugs
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions